BMRN:NGS-BioMarin Pharmaceutical Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 88.61

Change

+0.87 (+0.99)%

Market Cap

USD 14.69B

Volume

1.03M

Analyst Target

USD 111.27
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
ARGX argenx NV ADR

N/A

USD 22.16B
BNTX BioNTech SE

N/A

USD 21.93B
GMAB Genmab AS

N/A

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 18.12B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
SRPT Sarepta Therapeutics Inc

N/A

USD 12.17B

ETFs Containing BMRN

GNOM Global X Genomics & Biote.. 3.72 % 0.00 %

N/A

USD 0.09B
GDOC Goldman Sachs ETF Trust 3.31 % 0.00 %

N/A

USD 0.02B
IBBQ Invesco Nasdaq Biotechnol.. 1.91 % 0.00 %

N/A

USD 0.03B
BIS ProShares UltraShort Nasd.. 1.91 % 0.95 %

N/A

USD 3.52M
BMED BlackRock Future Health E.. 1.77 % 0.00 %

N/A

USD 4.21M
BTEC:SW iShares Nasdaq US Biotech.. 1.76 % 0.00 %

N/A

USD 0.46B
BIB ProShares Ultra Nasdaq Bi.. 1.38 % 0.95 %

N/A

USD 0.08B
ETHO Etho Climate Leadership U.. 0.39 % 0.45 %

N/A

USD 0.18B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

N/A

USD 0.11B
LABS 0.00 % 0.45 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

USD 0.23B
FCVT First Trust SSI Strategic.. 0.00 % 0.95 %

N/A

USD 0.08B
EASI 0.00 % 0.75 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.49B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.49B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

N/A

USD 8.18M
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.49B
UBIO 0.00 % 0.95 %

N/A

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A
XS2D:LSE Xtrackers S&P 500 2x Leve.. 0.00 % 0.00 %

N/A

USD 0.29B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
DBPG:F Xtrackers - S&P 500 2x Le.. 0.00 % 0.00 %

N/A

USD 0.32B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

USD 0.02B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
DBPG:XETRA Xtrackers S&P 500 2x Leve.. 0.00 % 0.00 %

N/A

USD 0.32B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.00 % 0.00 %

N/A

USD 4.28M
BIOT:SW L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.10% 38% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.10% 38% F 33% F
Trailing 12 Months  
Capital Gain -5.93% 53% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.93% 52% F 41% F
Trailing 5 Years  
Capital Gain -0.25% 72% C 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.25% 72% C 45% F
Average Annual (5 Year Horizon)  
Capital Gain 4.26% 63% D 62% D
Dividend Return 4.26% 63% D 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 17.76% 98% N/A 79% B-
Risk Adjusted Return 23.99% 79% B- 62% D
Market Capitalization 14.69B 99% N/A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 97.85 9% 11%
Price/Book Ratio 3.24 44% 33%
Price / Cash Flow Ratio 100.85 2% 3%
Price/Free Cash Flow Ratio 51.94 1% 4%
Management Effectiveness  
Return on Equity 3.51% 95% 64%
Return on Invested Capital 2.33% 85% 65%
Return on Assets 1.63% 96% 74%
Debt to Equity Ratio 11.98% 54% 67%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.